NCT05838092View on ClinicalTrials.gov

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)

PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 18, 2023

Primary Completion Date

December 1, 2024

Study Completion Date

December 1, 2025

Conditions

Epidermolysis Bullosa

Interventions

DRUG

allo-APZ2-OTS

Allogeneic dermal ABCB5-positive Mesenchymal Stromal Cells (ABCB5+ MSCs)

DRUG

Placebo

Trial Locations (1)

55455

RECRUITING

Masonic Cancer Center and Medical Center Minneapolis, Minneapolis

All Listed Sponsors

lead

RHEACELL GmbH & Co. KG

INDUSTRY

NCT05838092 - Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III) | Biotech Hunter | Biotech Hunter